As of Friday, December 12, Anixa Biosciences, Inc.’s ANIX share price has dipped by 18.33%, which has investors questioning if this is right time to buy.

Anixa Biosciences shares surged in after-hours trading after presenting clinical trial data for its investigational breast cancer vaccine.

ANIXA BIOSCIENCES INC (ANIX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

) has been revised to $10.20 / share. This is an increase of 11.11% from the prior estimate of $9.18 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has ANIXA BIOSCIENCES INC (ANIX) been one of those stocks this year? A quick glance ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

Anixa Biosciences is a biotech specializing in immunotherapy treatments for breast and ovarian cancers. They are developing a vaccine for α-lactalbumin in triple-negative breast cancer and AMHR2 in ...

ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one patient ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...